Understanding how BARD1 and PLK1 interactions affect pancreatic cancer treatment
Official title: Elucidating the relevance of BARD1-PLK1 interaction in PDAC and response to therapy
Funded at Thomas Jefferson University · NIH-10888373 · Data updated 2026-11-12
This study is looking at how a protein called BARD1 affects pancreatic cancer and its response to treatments, especially for patients with certain genetic changes, to find better ways to help those who have fewer treatment options.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 14, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $78,000 |
| NIH project number | 5R03CA283232-02 |
| Project ID | NIH-10888373 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, especially those with BRCA1/2 mutations or homologous recombination repair deficiencies.
✕Less likely to help
Patients with pancreatic cancer who do not have BRCA1/2 mutations or other related genetic deficiencies may not benefit from this research.
What this research studies
This research investigates the role of the BARD1 protein in pancreatic ductal adenocarcinoma (PDAC) and how it interacts with PLK1 to influence treatment responses. By studying the effects of BARD1 on cancer cell behavior, particularly in tumors with specific genetic mutations like BRCA1/2, the research aims to identify new therapeutic targets that could enhance the effectiveness of existing treatments. Patients with HRR deficient tumors may benefit from this approach, as the study seeks to improve treatment outcomes for those who currently have limited options.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for pancreatic cancer patients, particularly those with specific genetic profiles.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in other cancers, suggesting potential for success in this novel approach for pancreatic cancer.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Jain, Aditi — Thomas Jefferson University
- Study coordinator: Jain, Aditi
Related research
Other NIH-funded projects on the same topics.
-
Targeting epigenomic regulators to assault pancreatic cancer replication stress
This research tests a new way to treat pancreatic cancer by blocking key epigenetic regulators during DNA replication to make cancer cells less able to cope with replication stress.
-
Neoantigen vaccines in pancreatic cancer: overcoming resistance to improve immune responses
This grant supports testing advanced neoantigen vaccines in pancreatic cancer to boost patients' immune responses and potentially improve outcomes.
-
CD11b-activating drug to make pancreatic cancer respond to immunotherapy
A study to see if a CD11b-activating drug (GB1275) can help pancreatic cancer patients respond better to immunotherapy when combined with standard chemotherapy and PD-1 blockers.
-
Targeting autophagy to treat KRAS-mutant pancreatic cancer
This grant explores using approved drugs to block autophagy in KRAS-mutant pancreatic cancer to improve treatment outcomes.
-
Reprogramming PDAC stroma by targeting blood clotting in the tumor environment
A cancer research grant aimed at turning the tough, fibrous pancreatic cancer environment into one that helps treatments work better and supports the body’s immune response.
-
Understanding paracrine signals in pancreatic cancer to improve drug delivery
A patient-focused look at how the tumor’s signaling networks affect treatment delivery in pancreatic cancer and how targeting these networks could help therapies reach tumors more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.